LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Childhood Concussions Detected by Blood Test

By LabMedica International staff writers
Posted on 25 Nov 2015
Image: Immunohistochemistry of glial fibrillary acidic protein (GFAP) the major component of the filaments found in fibrillary and protoplasmic astrocytes in the brain. The protein is visualized as a brown deposit (Photo courtesy of Roy Ellis).
Image: Immunohistochemistry of glial fibrillary acidic protein (GFAP) the major component of the filaments found in fibrillary and protoplasmic astrocytes in the brain. The protein is visualized as a brown deposit (Photo courtesy of Roy Ellis).
A blood test has been developed that can detect even the most subtle signs of a concussion in children, correctly identifying the presence of traumatic brain injuries in the majority of cases.

Currently, almost all concussions in children are diagnosed only by symptoms, which are either observed, like vomiting or balance problems, or symptoms that are reported by the child, like headaches, blurred vision or feeling groggy. Neither scenario gives doctors an objective indication of the severity of the injury.

Doctors at the Orlando Regional Medical Center (Orlando, FL, USA) performed computerized tomography (CT) scans on 152 children and compared the results of those scans with results from the blood test they developed. As expected, the high definition imagery from the CT scans was able to identify which patients had suffered visible traumatic brain injuries. However, the study showed that the blood test detected symptoms of concussions, even when brain injuries were not visible on the CT scan.

The biomarker this particular blood test looks for is known as glial fibrillary acidic protein (GFAP). These proteins are found in glial cells, which surround neurons in the brain. Serum GFAP levels were measured in duplicate for each sample using a validated enzyme-linked immunosorbent assay (ELISA) platform (Banyan Biomarkers Inc.; Alachua, FL, USA). The lower limit of quantification for this assay is 0.03 ng/mL and upper limit of quantification is 50 ng/mL. The limit of detection is 0.008 pg/mL. Any sample yielding a signal over the quantification or calibrator range was diluted and re-assayed.

The team then tested blood serum from the same patients, which was taken less than six hours after their injuries. The blood test detected symptoms of concussions, even when brain injuries were not visible on the CT scan and can detect even the most subtle signs of a concussion in children, correctly identifying the presence of traumatic brain injuries 94% of the time. The authors envision envisions the development of mobile devices that could diagnose concussions on the spot, much like the devices diabetics use to test their blood with a simple finger prick and a drop of blood. Performance for detecting intracranial lesions at a GFAP cutoff level of 0.15 ng/mL yielded a sensitivity of 94%, a specificity of 47%, and a negative predictive value of 98%.

Linda Papa, MDCM, MSc, an emergency medicine physician and lead author of the study, said, “We were looking at different types of brain lesions detected by the CT scans, ranging from mild to serious injuries, and found that the biomarker we tested for actually corresponded to the injuries. Levels of the biomarker were lower in mild cases, and were much more elevated in severe case. If we could find a simple test that takes the guess work out of diagnosing these kids that would completely change the way we approach concussions and would certainly give parents greater peace of mind.” The study was published in the November 2015 issue of the journal Academic Emergency Medicine.

Related Links:

Orlando Regional Medical Center 
Banyan Biomarkers Inc. 


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more